Abstract
Background
0.6–12.7% of patients with primary cutaneous melanoma will develop additional melanomas. Pathologic features of tumors in patients with multiple primary cutaneous melanomas have not been well described. In this large, international, multicenter, case–control study, we compared the clinicopathologic features of a subsequent melanoma with the preceding (usually the first) melanoma in patients with multiple primary cutaneous melanomas, and with those of melanomas in patients with single primary cutaneous melanomas.
Methods
Multiple primary melanoma (cases) and single primary invasive melanoma (controls) patients from the Genes, Environment and Melanoma (GEM) study were included if their tumors were available for pathologic review and confirmed as melanoma. Clinicopathologic characteristics of invasive subsequent and first melanomas in cases and invasive single melanomas in controls were compared.
Results
A total of 473 pairs comprising a subsequent and a first melanoma and 1,989 single melanomas were reviewed. Forward stepwise regression modeling in 395 pairs with complete data showed that, compared with first melanomas, subsequent melanomas were more commonly contiguous with a dysplastic nevus, more prevalent on the head/neck and legs than other sites, and thinner. Compared with single primary melanomas, subsequent melanomas were more likely to be associated with a contiguous dysplastic nevus, more prevalent on the head/neck and legs, and thinner. The same differences were observed when subsequent melanomas were compared with single melanomas. First melanomas were more likely than single melanomas to have associated solar elastosis and no observed mitoses.
Conclusions
Thinner subsequent than first melanomas suggest earlier diagnosis, perhaps due to closer clinical scrutiny. The association of subsequent melanomas with dysplastic nevi is consistent with the latter being risk factors or risk markers for melanoma.
Similar content being viewed by others
References
Savoia P, Quaglino P, Verrone A, et al. Multiple primary melanomas: analysis of 49 cases. Melanoma Res. 1998;8(4):361–6.
Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647–54.
Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol. 2007;46(6):575–7.
Burden AD, Newell J, Andrew N, et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol. 1999;135(3):261–5.
Burden AD, Vestey JP, Sirel JM, et al. Multiple primary melanoma: risk factors and prognostic implications. BMJ. 1994;309(6951):375.
Lucchina LC, Barnhill RL, Duke DM, et al. Familial cutaneous melanoma. Melanoma Res. 1995;5(6):413–8.
Gupta BK, Piedmonte MR, Karakousis CP. Attributes and survival patterns of multiple primary cutaneous malignant melanoma. Cancer. 1991;67(7):1984–9.
Moseley HS, Giuliano AE, Storm FK, 3rd, et al. Multiple primary melanoma. Cancer. 1979;43(3):939–44.
Slingluff CL Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery. 1993;113(3):330–9.
Kang S, Barnhill RL, Mihm MC, Jr., et al. Multiple primary cutaneous melanomas. Cancer. 1992;70(7):1911–6.
Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA. 1978;239(8):744–6.
Frank W, Rogers GS. Melanoma update. Second primary melanoma. J Dermatol Surg Oncol. 1993;19(5):427–30.
Pack GT, Scharnagel IM, Hillyer RA. Multiple primary melanoma. Cancer. 1952;5(6):1110–5.
Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol. 1975;111(5):603–9.
Cascinelli N, Fontana V, Cataldo I, et al. Multiple primary melanoma. Tumori. 1975;61(5):481–6.
Scheibner A, Milton GW, McCarthy WH, et al. Multiple primary melanoma—a review of 90 cases. Australas J Dermatol. 1982;23(1):1–8.
Titus-Ernstoff L, Duray PH, Ernstoff MS, et al. Dysplastic nevi in association with multiple primary melanoma. Cancer Res. 1988;48(4):1016–8.
Ariyan S, Poo WJ, Bolognia J, et al. Multiple primary melanomas: data and significance. Plast Reconstr Surg. 1995;96(6):1384–9.
Giles G, Staples M, McCredie M, et al. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res. 1995;5(6):433–8.
Marghoob AA, Slade J, Kopf AW, et al. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol. 1996;135(5):704–11.
Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4(1):19–23.
Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol. 1998;39(3):422–7.
Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338(13):879–87.
Bhatia S, Estrada-Batres L, Maryon T, et al. Second primary tumors in patients with cutaneous malignant melanoma. Cancer. 1999;86(10):2014–20.
DiFronzo LA, Wanek LA, Elashoff R, et al. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6(7):705–11.
Wolff J, Wollina U. Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol. 2000;14(6):479–83.
DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer. 2001;91(8):1520–4.
Schmid-Wendtner MH, Baumert J, Wendtner CM, et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001;145(6):981–5.
Stam-Posthuma JJ, van Duinen C, Scheffer E, et al. Multiple primary melanomas. J Am Acad Dermatol. 2001;44(1):22–7.
Blackwood MA, Holmes R, Synnestvedt M, et al. Multiple primary melanoma revisited. Cancer. 2002;94(8):2248–55.
Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol. 2003;139(8):1013–8.
Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003;97(3):639–43.
Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142(4):433–8.
Bower MR, Scoggins CR, Martin RC 2nd, et al. Second primary melanomas: incidence and outcome. American Surgeon. 2010;76(7):675–81.
Begg CB, Hummer AJ, Mujumdar U, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006;35(3):756–64.
Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
Guerriere-Kovach PM, Hunt EL, Patterson JW, et al. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol. 2004;122(1):70–7.
Orlow I, Tommasi DV, Bloom B, et al. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol. 2009;129(8):1972–82.
Manganoni AM, Farisoglio C, Tucci G, et al. The importance of self-examination in the earliest diagnosis of multiple primary cutaneous melanomas: a report of 47 cases. J Eur Acad Dermatol Venereol. 2007;21(10):1333–6.
Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6(1):1–45.
Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol. 1986;14(5 Pt 1):857–60.
Carli P, De Giorgi V, Chiarugi A, et al. Multiple synchronous cutaneous melanomas: implications for prevention. Int J Dermatol. 2002;41(9):583–5.
Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer. 1999;86(11):2252–8.
Green A, MacLennan R, Youl P, et al. Site distribution of cutaneous melanoma in Queensland. Int J Cancer. 1993;53(2):232–6.
Whiteman DC, Bray CA, Siskind V, et al. A comparison of the anatomic distribution of cutaneous melanoma in two populations with different levels of sunlight: the west of Scotland and Queensland, Australia 1982–2001. Cancer Causes Control. 2007;18(5):485–91.
Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control. 2007;18(3):295–304.
Duncan LM. The classification of cutaneous melanoma. Hematol Oncol Clin North Am. 2009;23(3):501–13, ix.
Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45(12):3012–7.
Lock-Andersen J, Hou-Jensen K, Hansen JP, et al. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg. 1995;29(2):141–8.
Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14(4):1218–23.
Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet. 1984;1(8379):729.
Greene MH, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med. 1985;102(4):458–65.
Tucker MA, Fraser MC, Goldstein AM, et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 1993;100(3):350S–5S.
Carey WP, Jr., Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer. 1994;74(12):3118–25.
Acknowledgment
This work is supported by the following NIH/NCI grants: U01 CA83180, R01 CA112425, R01 CA112243, and R01 CA112243-05S1. Professor Scolyer is a Cancer Institute New South Wales Clinical Research Fellow.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
This study is conducted for the GEM Study Group. The list of GEM Study Group who conducted in this study are given in Appendix.
Appendix
Appendix
The following persons conducted in this study: Marianne Berwick (PI, University of New Mexico), Memorial Sloan-Kettering Cancer Center, New York, NY, USA: Colin Begg (Co-PI), Irene Orlow (Co-Investigator), Urvi Mujumdar (Project Coordinator), Klaus Busam (Dermatopathologist), Pampa Roy (Laboratory Technician). Study Centers: The University of Sydney and The Cancer Council New South Wales, Sydney (Australia): Bruce Armstrong (PI), Anne Kricker (co-PI), Melisa Litchfield (Study Coordinator). Menzies Research Institute, University of Tasmania, Hobart (Australia): Terence Dwyer (PI, currently at the Murdoch Childrens Research Institute, Melbourne, Victoria), Paul Tucker (Dermatopathologist), Alison Venn (co-Investigator), Nicola Stephens (Study Coordinator). British Columbia Cancer Agency, Vancouver (Canada): Richard Gallagher (PI), Teresa Switzer (Coordinator). Cancer Care Ontario, Toronto (Canada): Loraine Marrett (PI), Elizabeth Theis (Co-Investigator), Lynn From (Dermatopathologist), Noori Chowdhury (Coordinator), Louise Vanasse (Coordinator). Centro per la Prevenzione Oncologia Torino, Piemonte (Italy): Stefano Rosso (PI), Roberto Zanetti (co-PI), Carlotta Sacerdote (Coordinator). University of California, Irvine (USA): Hoda Anton-Culver (PI), Nancy Leighton (Coordinator). University of Michigan, Ann Arbor (USA): Stephen Gruber (PI), Joanne Jeter (Coordinator). New Jersey Department of Health and Senior Services, Trenton (USA): Judith Klotz (PI), Homer Wilcox (Co-PI), Helen Weiss (Coordinator). University of North Carolina, Chapel Hill (USA): Robert Millikan (PI), Nancy Thomas (Co-Investigator), Dianne Mattingly (Coordinator), Jon Player (Laboratory Technician). University of Pennsylvania, Philadelphia, PA (USA): Timothy Rebbeck (PI), Peter Kanetsky (Co-Investigator), Amy Walker (Laboratory Manager), Saarene Panossian (Laboratory Technician). Consultants: Julia Lee Taylor and Sasha Madronich, National Centre for Atmospheric Research, Boulder, Colorado (USA).
Rights and permissions
About this article
Cite this article
Murali, R., Goumas, C., Kricker, A. et al. Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. Ann Surg Oncol 19, 1024–1033 (2012). https://doi.org/10.1245/s10434-011-2058-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-2058-8